World Class Team Will Provide Strategic
Guidance and Direction for PacBio's Research and Development
Activities
MENLO
PARK, Calif., Nov. 2, 2022
/PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of
high-quality, highly accurate sequencing solutions, today announced
it is bringing together a group of scientific experts to form
PacBio's Scientific Advisory Board (SAB). The SAB will provide
guidance to the research and development efforts at PacBio,
including critical feedback, advice, and expertise on future
technological and scientific direction to inform PacBio's
priorities and roadmaps for current and future products. The goal
of the SAB is to help provide a strong voice for the future of the
'omics and quantitative biology fields, while advocating for ways
PacBio can create that future.
SAB members were chosen based on their leadership in fields such
as biophysics, genomics, medicine, biology, chemistry and/or chip
fabrication. The SAB will be made up initially of the following
individuals:
- Euan Ashley, M.D., Ph.D. –
Associate Dean and Professor of Medicine, School of Medicine, Roger
and Joelle Burnell Professor of Genomics and Precision Health at
Stanford University
Dr. Ashley graduated with 1st class Honors in
Physiology and Medicine from the University of
Glasgow. He completed medical residency and a Ph.D. at the
University of Oxford before moving to
Stanford University where he trained in
cardiology and advanced heart failure, joining the faculty in 2006.
His group is focused on the science of precision medicine. In 2010,
he led the team that carried out the first clinical interpretation
of a human genome. The article became one of the most cited in
clinical medicine that year and was later featured in the Genome
Exhibition at the Smithsonian in DC. Over the following three
years, the team extended the approach to the first whole genome
molecular autopsy, to a family of four, and to a case series of
patients in primary care. They now routinely apply genome
sequencing to the diagnosis of patients at Stanford hospital where Dr. Ashley directs the
Clinical Genome Program and the Center for Inherited Cardiovascular
Disease. Dr. Ashley has a passion for rare genetic disease and was
the first co-chair of the steering committee of the Undiagnosed
Diseases Network. He was a recipient of the National Innovation
Award from the American Heart Association and the NIH Director's
New Innovator Award.
- Joseph (Jody) Puglisi, Ph.D. –
Jauch Professor and Professor of Structural Biology at Stanford University
Dr. Puglisi is a leading scientist in the study
of RNA structure and function in biology. He pioneered the use of
NMR in the study of RNAs and RNA-ligand complexes. His early work
showed how small molecules can bind to RNAs, which has led to the
field of RNA as a drug target and riboswitches. Recent work has
merged novel single-molecule approaches biochemical and structural
methods to merge dynamic and static structural views of essential
RNA mechanisms, including translation and viral infections.
Dr. Puglisi received his Ph.D. in Biophysical
Chemistry from University of California,
Berkeley. After postdoctoral training at I.B.M.C du CNRS in
Strasbourg and Massachusetts Institute of Technology, Cambridge he returned to California, first as assistant professor at
University of California, Santa Cruz
and in 1997 as associate professor at Stanford
University, School of Medicine. In 2004 he was appointed
professor in Structural Biology at Stanford and the same year he was elected chair of
the Department of Structural Biology. Dr. Puglisi was awarded the
NIH Director's Transformative R01 (T-R01) Program Award in 2011 and
the same year he was also granted the NIH Merit Award. In 2014, he
was elected member of the National Academy of Sciences.
- Jay Shendure, Ph.D. – Professor
of Genome Sciences at University of
Washington
Dr. Shendure is an Investigator of the Howard
Hughes Medical Institute, Professor of Genome Sciences at the
University of Washington, and Director
of Brotman Baty Institute for Precision Medicine. His 2005 Ph.D.
included one of the first successful demonstrations of massively
parallel or next generation DNA sequencing. Dr. Shendure's research
group in Seattle pioneered exome
sequencing and its earliest applications to gene discovery for
Mendelian disorders (e.g. Miller and Kabuki syndrome) and autism;
cell-free DNA diagnostics for cancer and reproductive medicine;
massively parallel reporter assays and saturation genome editing;
whole organism lineage tracing; and massively parallel molecular
profiling of single cells. He is the recipient of the 2012 Curt
Stern Award from the American Society of Human Genetics, the 2013
FEDERAprijs, a 2013 NIH Director's Pioneer Award, and the 2022
Mendel Prize from the European Society of Human Genetics. He is an
elected member of the American Association for the Advancement of
Science and the US National Academy of Sciences.
"We are thrilled to have scientific advisory board members who
are on the forefront of genomics from both a technology and
clinical perspective," said Christian
Henry, President and Chief Executive Officer of PacBio. "I
am confident that their expertise will help guide PacBio's
innovation to develop new products and technologies that will push
the field of genomics forward."
"I am honored and delighted to join PacBio's scientific advisory
board," said Jody Puglisi, Ph.D.,
Jauch Professor and Professor of Structural Biology at Stanford University. "The commitment to their
mission to enable the promise of genomics to better human health is
evident in everything they do. Their recent new product
announcements – the Revio and Onso sequencing systems – are a
testament to their scientific depth, creativity, and willingness to
listen and learn as they develop future products."
About PacBio
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier
life science technology company that is designing, developing and
manufacturing advanced sequencing solutions to help scientists and
clinical researchers resolve genetically complex problems. Our
products and technology under development stem from two highly
differentiated core technologies focused on accuracy, quality and
completeness which include our existing HiFi long read sequencing
and our emerging SBB™ short read sequencing technologies. Our
products address solutions across a broad set of research
applications including human germline sequencing, plant and animal
sciences, infectious disease and microbiology, oncology, and other
emerging applications. For more information, please visit
www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in
diagnostic procedures.
Forward-Looking
Statements
This press release contains "forward-looking statements" within
the meaning of Section 21E of the Securities Exchange Act of 1934,
as amended, and the U.S. Private Securities Litigation Reform Act
of 1995. All statements other than statements of historical fact
are forward-looking statements, including statements relating to
anticipated guidance by, and the goals of, the SAB, including in
connection with the development of new products and technologies;
the initial number of SAB members; and other future events. Readers
are cautioned not to place undue reliance on these forward-looking
statements and any such forward-looking statements are qualified in
their entirety by reference to the following cautionary statements.
All forward-looking statements speak only as of the date of this
press release and are based on current expectations and involve a
number of assumptions, risks and uncertainties that could cause the
actual results to differ materially from such forward-looking
statements, including, among others, challenges inherent in
developing new products; potential conflicts and obligations of SAB
members with third parties; and extensive competition in genomic
sequencing that could make the products PacBio is developing,
including any that it may develop in connection with input from the
SAB, obsolete or non-competitive. Readers are strongly encouraged
to read the full cautionary statements contained in PacBio's
filings with the Securities and Exchange Commission, including the
risks set forth in the company's Forms 8-K, 10-K, and 10-Q. PacBio
disclaims any obligation to update or revise any forward-looking
statements.
Contacts
Investors:
Todd
Friedman
650.521.8450
ir@pacb.com
Media:
Lizelda
Lopez
pr@pacb.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pacbio-announces-that-euan-ashley-md-phd-joseph-puglisi-phd-and-jay-shendure-phd-join-newly-created-scientific-advisory-board-301665625.html
SOURCE Pacific Biosciences of California, Inc.